TIME COURSE OF TREATMENT-RELATED ADVERSE EVENTS (TRAES) DURING DOSTARLIMAB THERAPY IN THE GARNET TRIAL

被引：0

作者：

Pothuri, Bhavana ^{[1
,2
]}

Berton, Dominique ^{[3
,4
]}

Moreno, Victor ^{[5
]}

Oaknin, Ana ^{[6
]}

Perez, Jose Manuel Trigo ^{[7
]}

Curigliano, Giuseppe ^{[8
,9
]}

Ellard, Susan ^{[10
]}

Pikiel, Joanna ^{[11
]}

Banerjee, Susana ^{[12
,13
]}

Barretina-Ginesta, Maria-Pilar ^{[14
]}

Miller, Rowan ^{[15
]}

Tinker, Anna ^{[16
]}

Jewell, Andrea ^{[17
]}

Plummer, Ruth ^{[18
]}

Joly, Florence ^{[19
]}

Veneris, Jennifer ^{[20
]}

Duan, Tao ^{[20
]}

Andre, Thierry ^{[21
,22
]}

机构：

[1] NYU Langone Hlth, Perlmutter Canc Ctr, Gynecol Oncol Grp GOG, New York, NY USA

[2] NYU Langone Hlth, Perlmutter Canc Ctr, Dept Obstet Gynecol, New York, NY USA

[3] Ctr Rene Gauducheau, GINECO, St Herblain, France

[4] Ctr Rene Gauducheau, Inst Cancerol Ouest, St Herblain, France

[5] Fdn Jimenez Diaz Hosp, START Madrid FJD, Madrid, Spain

[6] Vall dHebron Univ Hosp, Vall dHebron Inst Oncol VHIO, Barcelona, Spain

[7] Hosp Virgen Victoria IBIMA, Med Oncol Dept, Malaga, Spain

[8] IRCCS, European Inst Oncol, IEO, Div Early Drug Dev Innovat Therapies, Milan, Italy

[9] Univ Milan, Milan, Italy

[10] BC Canc Kelowna, Kelowna, BC, Canada

[11] Reg Ctr Oncol, Gdansk, Poland

[12] Royal Marsden NHS Fdn Trust, London, England

[13] Inst Canc Res, London, England

[14] Hosp Univ Dr J Trueta, Inst Catala Oncol, Girona, Spain

[15] UCL, St Bartholomews Hosp London, London, England

[16] BC Canc, Vancouver, BC, Canada

[17] Univ Kansas, Med Ctr, Kansas City, KS 66103 USA

[18] Newcastle Univ, Med Sch, Northern Inst Canc Res, London, England

[19] Ctr Francois Baclesse, Med Oncol Dept, Caen, France

[20] GlaxoSmithKline, London, England

[21] Sorbonne Univ, Paris, France

[22] St Antoine Hosp, Paris, France

来源：

JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2021年 / 9卷

关键词：

D O I：

10.1136/jitc-2021-SITC2021.370

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

370

引用

页码：A398 / A398

页数：1

共 50 条

[41] Improving Report of the ADAURA Trial by Distinguishing Treatment-Related Adverse Events From Treatment-Emergent Adverse Events and Assessing Independence of Censoring in Final Disease-Free Survival Analyses
Wu, Danna
Li, Guo-Fu
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (26) : 4317 - +
[42] MANAGEMENT OF TREATMENT-RELATED ADVERSE EVENTS ASSOCIATED WITH NIVOLUMAB AND IPILIMUMAB COMBINATION THERAPY IN PATIENTS WITH METASTATIC MELANOMA, NSCLC, OR RCC.
Kannan, Rajni
Mitchell, Teresa
Sherry, Victoria
Pons, Alice
Kreamer, Kristen
Shames, Yelena
ONCOLOGY NURSING FORUM, 2017, 44 (02)
[43] Risk factors for treatment-related adverse events in cancer-bearing dogs receiving piroxicam
Eichstadt, L. R.
Moore, G. E.
Childress, M. O.
VETERINARY AND COMPARATIVE ONCOLOGY, 2017, 15 (04) : 1346 - 1353
[44] Improving report of the ADAURA trial by distinguishing treatment-related adverse events from treatment-emergent adverse events and assessing independence of censoring in final disease-free survival analyses Reply
Herbst, Roy S.
Wu, Yi-Long
Tsuboi, Masahiro
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (26) : 4318 - U168
[45] Tolerability and Treatment-Related Adverse Events of Upfront Pembrolizumab Combination Regimens in Advanced NSCLC Patients
Jahan, N.
Thein, K.
Sultan, A.
Swarup, S.
Mogollon-Duffo, F.
Adhikari, N.
Arevalo, M.
Htut, T.
Naing, T.
D'Cunha, N.
Rehman, S.
Hardwicke, F.
Tijani, L.
JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S726 - S726
[46] Treatment-Related Serious Adverse Events of Immune Checkpoint Inhibitors in Clinical Trials: A Systematic Review
Ouyang, Tao
Cao, Yanyan
Kan, Xuefeng
Chen, Lei
Ren, Yanqiao
Sun, Tao
Yan, Liangliang
Xiong, Bin
Liang, Bin
Zheng, Chuansheng
FRONTIERS IN ONCOLOGY, 2021, 11
[47] CLINICAL OUTCOMES AND TREATMENT-RELATED ADVERSE EVENTS TO TOCILIZUMAB IN SARS-COV-2 ILLNESS
Ahmad, S.
Jenkinson, E.
Carney, R.
Nahu, T.
Quinn, J.
Dwarakanath, A.
THORAX, 2021, 76 : A169 - A169
[48] Management of Treatment-Related Adverse Events with Agents Targeting the MAPK Pathway in Patients with Metastatic Melanoma
Daud, Adil
Tsai, Katy
ONCOLOGIST, 2017, 22 (07): : 823 - 833
[49] The role of age in treatment-related adverse events in patients with head and neck cancer: A systematic review
Coca-Pelaz, Andres
Halmos, Gyorgy B.
Strojan, Primoz
de Bree, Remco
Bossi, Paolo
Bradford, Carol R.
Rinaldo, Alessandra
Vander Poorten, Vincent
Sanabria, Alvaro
Takes, Robert P.
Ferlito, Alfio
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2019, 41 (07): : 2410 - 2429
[50] Gastrointestinal treatment-related adverse events of combined immune checkpoint inhibitors: a meta-analysis
Karna, Rahul
S Deliwala, Smit
Ramgopal, Balasubramanian
Asawa, Palash
Mishra, Rahul
P Mohan, Babu
Jayakrishnan, Thejus
Grover, Dheera
Kalra, Tanisha
Bhalla, Jaideep
Saraswati, Ushasi
Gangwani, Manesh K.
Dhawan, Manish
Adler, Douglas G.
IMMUNOTHERAPY, 2023, 15 (10) : 773 - 786

← 1 2 3 4 5 →